المؤلفون: Prat A., Guarneri V., Pare L., Griguolo G., Pascual T., Dieci M. V., Chic N., Gonzalez-Farre B., Frassoldati A., Sanfeliu E., Cejalvo J. M., Munoz M., Bisagni G., Braso-Maristany F., Urso L., Vidal M., Brandes A. A., Adamo B., Musolino A., Miglietta F., Conte B., Oliveira M., Saura C., Pernas S., Alarcon J., Llombart-Cussac A., Cortes J., Manso L., Lopez R., Ciruelos E., Schettini F., Villagrasa P., Carey L. A., Perou C. M., Piacentini F., D'Amico R., Tagliafico E., Parker J. S., Conte P.

المساهمون: Prat, A., Guarneri, V., Pare, L., Griguolo, G., Pascual, T., Dieci, M. V., Chic, N., Gonzalez-Farre, B., Frassoldati, A., Sanfeliu, E., Cejalvo, J. M., Munoz, M., Bisagni, G., Braso-Maristany, F., Urso, L., Vidal, M., Brandes, A. A., Adamo, B., Musolino, A., Miglietta, F., Conte, B., Oliveira, M., Saura, C., Pernas, S., Alarcon, J., Llombart-Cussac, A., Cortes, J., Manso, L., Lopez, R., Ciruelos, E., Schettini, F., Villagrasa, P., Carey, L. A., Perou, C. M., Piacentini, F., D'Amico, R., Tagliafico, E., Parker, J. S., Conte, P.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000584488100048; volume:21; issue:11; firstpage:1455; lastpage:1464; numberofpages:10; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/11381/2882684Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85094842387

الإتاحة: https://doi.org/10.1016/S1470-2045Test(20)30450-2
http://hdl.handle.net/11381/2882684Test

المؤلفون: Prat, A., Guarneri, V., Paré, L., Griguolo, G., Pascual, T., Dieci, M.V., Chic, N., González-Farré, B., Frassoldati, A., Sanfeliu, E., Cejalvo, J.M., Muñoz, M., Bisagni, G., Brasó-Maristany, F., Urso, L., Vidal, M., Brandes, A.A., Adamo, B., Musolino, A., Miglietta, F., Conte, B., Oliveira, M., Saura, C., Pernas, S., Alarcón, J., Llombart-Cussac, A., Cortés, J., Manso, L., López, R., Ciruelos, E., Schettini, F., Villagrasa, P., Carey, L.A., Perou, C.M., Piacentini, F., D'Amico, R., Tagliafico, E., Parker, J.S., Conte, P.

المصدر: The Lancet Oncology, 21(11)

مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols, Trastuzumab, Antibodies, Monoclonal, Humanized, Female, Neoplasm Recurrence, Local, Disease-Free Survival, Neoplasm Staging, Adult, Receptor, ErbB-2, Breast Neoplasms, Bridged-Ring Compounds, Proportional Hazards Models, Humans, Prognosis, Neoadjuvant Therapy, Aged, Biomarkers, Tumor, Taxoids, Middle Aged, Gene Expression Regulation, Neoplastic, Treatment Outcome

العلاقة: https://doi.org/10.17615/hpvv-f686Test; https://cdr.lib.unc.edu/downloads/9k41zp25v?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/9k41zp25vTest

الإتاحة: https://doi.org/10.17615/hpvv-f686Test
https://cdr.lib.unc.edu/downloads/9k41zp25v?file=thumbnailTest
https://cdr.lib.unc.edu/downloads/9k41zp25vTest